<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5040">
  <stage>Registered</stage>
  <submitdate>25/07/2013</submitdate>
  <approvaldate>25/07/2013</approvaldate>
  <nctid>NCT01927068</nctid>
  <trial_identification>
    <studytitle>Global Study of a Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal Lesions</studytitle>
    <scientifictitle>ILLUMENATE GLOBAL and ISR: Prospective, Single-Arm, Global Multi-Center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery (SFA) and/or Popliteal Lesions With a Novel Paclitaxel-Coated Percutaneous Angioplasty (PTA) Balloon and in In-Stent Restenosis</scientifictitle>
    <utrn />
    <trialacronym>ILLUMENATE</trialacronym>
    <secondaryid>CP-1005</secondaryid>
    <secondaryid>CP-1005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Arterial Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - CVI Paclitaxel-Coated PTA Balloon Catheter

Experimental: CVI Paclitaxel-Coated PTA Balloon Catheter - 


Treatment: devices: CVI Paclitaxel-Coated PTA Balloon Catheter
Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Safety Endpoint - Freedom from device and procedure-related death through 30 days post-procedure and freedom from target limb major amputation and clinically-driven target lesion revascularization (TLR) through 12 months post-procedure.</outcome>
      <timepoint>Through 30 days post-procedure.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary Efficacy Endpoint - Primary patency at 12 months post-procedure. Primary patency is defined as the absence of target lesion restenosis per duplex ultrasound (peak systolic velocity ratio (PSVR) = 2.5) and freedom from clinically-driven target lesion revascularization.</outcome>
      <timepoint>12 months post-procedure.</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Cohort 1: General 

          1. Has symptomatic leg ischemia, requiring treatment of the SFA and/or popliteal artery.

          2. Has a Rutherford Clinical Category of 2 - 4. Note: Rutherford Clinical Category 2
             subjects should be entered into the study if conservative treatment has been
             unsuccessful.

          3. Is =18 years old.

          4. Has life expectancy &gt;1 year.

          5. Is able and willing to provide written informed consent prior to study specific
             procedures.

          6. Is willing and capable of complying with the required follow-up visits, testing
             schedule and medication regimen.

        Cohort 1: Angiographic 

          1. Has evidence at the target lesion(s) of clinically and hemodynamically significant de
             novo stenosis or restenosis, or occlusion, in the SFA (1 cm distal to the ostium of
             the profunda) and/or popliteal artery (proximal to the popliteal trifurcation),
             confirmed by angiography.

          2. Has target limb with at least one patent (&lt;50% stenosis) tibio-peroneal run-off vessel
             to the foot confirmed by baseline angiography or magnetic resonance angiography (MRA)
             or computed tomography angiography (CTA). Note: Treatment of outflow disease is NOT
             permitted.

          3. Has 1 or 2 target lesion(s) with a cumulative lesion(s) length of no more than 20 cm.
             Note: A maximum of two (2) lesions can be treated if the cumulative total lesion
             length (i.e. the combined length of both lesions) is less than or equal to 20cm.

          4. Has target lesion(s) located &gt;2 cm from any stent if the target vessel was previously
             stented.

          5. Has a reference vessel diameter of 4 - 6 mm by visual estimate.

          6. Has a successful exchangeable guidewire crossing of the lesion(s).

        Cohort 1: General</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. A female who is pregnant, of childbearing potential not taking adequate contraceptive
             measures, or nursing; or a male intending to father children during the study.

          2. Has significant gastrointestinal bleeding or any coagulopathy that would
             contraindicate the use of anti-platelet therapy

          3. Has known intolerance to study medications, paclitaxel or contrast agents that in the
             opinion of the investigator cannot be adequately pre-treated.

          4. Is currently participating in another investigational device or drug study that would
             interfere with study endpoints.

          5. Has history of hemorrhagic stroke within 3 months.

          6. Has surgical or endovascular procedure of the target limb within 14 days prior to the
             index procedure.

          7. Has any planned surgical intervention (requiring hospitalization) or endovascular
             procedure within 30 days after the index procedure.

          8. Has had a previous peripheral bypass affecting the target limb.

          9. Has unstable angina pectoris, myocardial infarction, liver failure, renal failure or
             chronic kidney disease (dialysis dependent, or serum creatinine =2.5 mg/dL) within 30
             days of the index procedure.

        Cohort 1: Angiographic 

          1. Has significant stenosis (=50%) or occlusion of inflow tract that is not successfully
             revascularized (&lt;30% residual stenosis without death or major vascular complication)
             prior to treatment of the target lesion(s). Only treatment of target lesion(s) is
             acceptable after successful treatment of inflow iliac artery lesion(s).

          2. Has an acute or sub-acute intraluminal thrombus within the target vessel.

          3. Has in-stent restenosis or restenosis of the target lesion following previous
             treatment with a drug-coated balloon.

          4. Has an aneurysm (at least twice the reference vessel diameter) located in the target
             vessel, abdominal aorta, iliac, or popliteal arteries.

          5. Has perforation, dissection or other injury of the access or target vessel requiring
             stenting or surgical intervention prior to enrollment.

          6. Has no normal arterial segment proximal to the target lesion in which duplex
             ultrasound velocity ratios can be measured.

          7. Requires use of adjunctive therapies (i.e., laser, atherectomy, cryoplasty,
             scoring/cutting balloons, brachytherapy).

          8. Has severe calcification that precludes adequate PTA treatment.

        Cohort 2: General Inclusion Criteria:

          1. Has symptomatic leg ischemia, requiring treatment of the SFA and/or popliteal artery.

          2. Has a Rutherford Clinical Category of 2 - 4. Note: Rutherford Clinical Category 2
             subjects should be entered into the study if conservative treatment has been
             unsuccessful.

          3. Is between 18-85 years old.

          4. Has life expectancy &gt;1 year.

          5. Is able and willing to provide written informed consent prior to study specific
             procedures.

          6. Is willing and capable of complying with the required follow-up visits, testing
             schedule and medication regimen.

          7. History of previous femoropopliteal nitinol stenting which is suspect for in-stent
             restenosis.

          8. The patient has a resting ankle-brachial index (ABI) &lt;0.9 or an abnormal exercise ABI
             (&lt;0.9) if resting ABI is normal. Patient with incompressible arteries (ABI&gt;1.2) must
             have a toe-brachial index (TBI) &lt;0.7 in target limb.

        Cohort 2: Angiographic Inclusion Criteria:

          1. Has angiographic evidence of significant restenosis (=50% by visual estimate) within a
             previously deployed femoropopliteal bare nitinol stent(s) including ISR Class I, II or
             III.

          2. Has target limb with at least one patent (&lt;50% stenosis) tibio-peroneal run-off vessel
             to the foot confirmed by baseline angiography or magnetic resonance angiography (MRA)
             or computed tomography angiography (CTA). Note: Treatment of outflow disease is NOT
             permitted.

          3. Total target treatment length of in-stent restenosis must be =4.0 cm in length and may
             include a single lesion or a multifocal lesion within the femoropopliteal segment
             (This includes the proximal, mid, and/or distal SFA and PI, P2 and/or P3 segment of
             the popliteal artery). Edge restenosis may be treated provided the lesion extends no
             more than 3 cm outside the margin of the stent (proximal and/or distal margin).

          4. Has target lesion(s) located &gt;2 cm from any stent if the target vessel was previously
             stented.

          5. Has a reference vessel diameter of 4 - 6 mm by visual estimate.

          6. Has a successful exchangeable guidewire crossing of the lesion(s).

        Cohort 2: General 

          1. A female who is pregnant, of childbearing potential not taking adequate contraceptive
             measures, or nursing; or a male intending to father children during the study.

          2. Has significant gastrointestinal bleeding or any coagulopathy that would
             contraindicate the use of anti-platelet therapy.

          3. Has known intolerance to study medications, paclitaxel or contrast agents that in the
             opinion of the investigator cannot be adequately pre-treated.

          4. Is currently participating in another investigational device or drug study that would
             interfere with study endpoints.

          5. Has history of hemorrhagic stroke within 3 months including those within &lt;60 days with
             an unresolved walking impairment.

          6. Has surgical or endovascular procedure of the target limb within 3 months prior to the
             index procedure.

          7. Has any planned surgical intervention (requiring hospitalization) or endovascular
             procedure within 30 days after the index procedure.

          8. Has had a previous peripheral bypass affecting the target limb.

          9. Has unstable angina pectoris, myocardial infarction within 60 days, liver failure,
             renal failure or chronic kidney disease (dialysis dependent, or serum creatinine =2.5
             mg/dL) within 30 days of the index procedure.

         10. History of previous femoropopliteal stenting in the target lesion with drug eluting
             stents or covered stents (endografts).

        Cohort 2: Angiographic 

          1. Ipsilateral and/or contralateral iliac (or common femoral) artery stenosis

             =50% diameter stenosis (DS) that is not successfully treated prior to index procedure
             (e.g. where a perforation occurred requiring a covered stent) or with final residual
             stenosis = 30% documented by angiography.

          2. Identification of any lesion of the native vessel (excludes ISR) above the target
             stent in the femoropopliteal segment &gt;50% that is not successfully treated prior to
             index procedure (e.g. complication requiring additional treatment) or with final
             residual stenosis &gt;30% documented by angiography. Drug eluting stent (DES) and drug
             coated balloon (DCB) will not be allowed. The lesion length must be treatable with a
             single stent (if required). The lesion must not be contiguous with the target lesion;
             at least 2 cm of normal appearing vessel between the lesion and target lesion/ target
             stent or between deployed stent (if required) and the target lesion/ target stent.

          3. Has an acute or sub-acute intraluminal thrombus within the target vessel.

          4. Has an aneurysm (at least twice the reference vessel diameter) located in the target
             vessel, abdominal aorta, iliac, or popliteal arteries.

          5. Has perforation, dissection or other injury of the access or target vessel requiring
             stenting or surgical intervention prior to enrollment.

          6. Has no normal arterial segment proximal to the target lesion in which duplex
             ultrasound velocity ratios can be measured.

          7. Requires use of adjunctive therapies (i.e., laser, atherectomy, cryoplasty,
             scoring/cutting balloons, brachytherapy).

          8. Grade 4 or 5 stent fracture affecting target stent or proximal to the target stent, or
             where evidence of stent protrusion into the lumen is noted on angiography in 2
             orthogonal views.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>501</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Wesley St. Andrew Research Institute Ltd. - Auchenflower</hospital>
    <hospital>Flinders Medical Centre - Bedford</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>Monash Medical Centre at Dandenong Campus - Clayton Victoria</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode> - Auchenflower</postcode>
    <postcode> - Bedford</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Clayton Victoria</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Aalst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bonheiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Dendermonde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Tienen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont-Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Krozingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Immenstadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Karlsbad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tübingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ancona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Perugia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Spectranetics Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Cohort 1: Single-Arm, multicenter study to continue to assess the safety and performance of
      the Cardiovascular Ingenuity (CVI) Paclitaxel-Coated PTA Balloon Catheter in the treatment of
      de novo or restenotic lesions in the superficial femoral and/or popliteal arteries Cohort 2:
      To evaluate this patient population for treatment of in-stent restenotic lesions</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01927068</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Thomas Zeller, MBChB, FRANZCR</name>
      <address>Herz-Zentrum Bad Krozingen, Germany</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Karen Krygier, MBA</name>
      <address />
      <phone>+1.763.923.4993</phone>
      <fax />
      <email>karen.krygier@spnc.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>